Cite
HARVARD Citation
Schreiber, S. et al. (n.d.). S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. American journal of gastroenterology. pp. S314-S315. [Online].